Quick Takeaways: Why It Matters? Gallant’s positive UMSC pilot data and FDA CVM’s expanded conditional approval eligibility together position this program as a potential first‑in‑class, disease‑modifying biologic in an almost empty feline OA toolbox. By showing up to...
